# Doximity, Inc.: financial statements, quarterly

DOCS · NYSE · CIK 1516513 · [Technology](/sectors/technology.md) · fiscal year ends Mar 31

Pages: [Overview](/companies/docs.md) · [Financials](/companies/docs/financials.md) · [Filings](/companies/docs/filings.md) · [Insiders](/companies/docs/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/docs/financials.md?period=annual).

## Income statement

| Line item | Unit | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | Q4 FY2024 (2024-03-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q4 FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q4 FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [114](/filings/0001516513-24-000102.md) | [135](/filings/0001516513-25-000012.md) | [118 d](/filings/0001516513-26-000025.md) | [127](/filings/0001516513-25-000093.md) | [137](/filings/0001516513-25-000111.md) | [169](/filings/0001516513-26-000006.md) | [138 d](/filings/0001516513-26-000025.md) | [146](/filings/0001516513-26-000040.md) | [169](/filings/0001516513-25-000111.md) | [185](/filings/0001516513-26-000006.md) | [145 d](/filings/0001516513-26-000025.md) | [157](/filings/0001516513-26-000040.md) |
| Cost of revenue | $m | [12.8](/filings/0001516513-24-000102.md) | [12.2](/filings/0001516513-25-000012.md) | [12.6 d](/filings/0001516513-26-000025.md) | [13.6](/filings/0001516513-25-000093.md) | [13.7](/filings/0001516513-25-000111.md) | [14.2](/filings/0001516513-26-000006.md) | [14.5 d](/filings/0001516513-26-000025.md) | [15.8](/filings/0001516513-26-000040.md) | [16.4](/filings/0001516513-25-000111.md) | [18.7](/filings/0001516513-26-000006.md) | [19.4 d](/filings/0001516513-26-000025.md) | [23.7](/filings/0001516513-26-000040.md) |
| Gross profit | $m | [101](/filings/0001516513-24-000102.md) | [123](/filings/0001516513-25-000012.md) | [105 d](/filings/0001516513-26-000025.md) | [113](/filings/0001516513-25-000093.md) | [123](/filings/0001516513-25-000111.md) | [154](/filings/0001516513-26-000006.md) | [124 d](/filings/0001516513-26-000025.md) | [130](/filings/0001516513-26-000040.md) | [152](/filings/0001516513-25-000111.md) | [166](/filings/0001516513-26-000006.md) | [126 d](/filings/0001516513-26-000025.md) | [133](/filings/0001516513-26-000040.md) |
| Research and development | $m | [20.0](/filings/0001516513-24-000102.md) | [19.9](/filings/0001516513-25-000012.md) | [20.1 d](/filings/0001516513-26-000025.md) | [22.6](/filings/0001516513-25-000093.md) | [23.2](/filings/0001516513-25-000111.md) | [22.4](/filings/0001516513-26-000006.md) | [24.8 d](/filings/0001516513-26-000025.md) | [26.8](/filings/0001516513-26-000040.md) | [30.2](/filings/0001516513-25-000111.md) | [34.6](/filings/0001516513-26-000006.md) | [39.1 d](/filings/0001516513-26-000025.md) | [38.5](/filings/0001516513-26-000040.md) |
| Operating income | $m | [33.8](/filings/0001516513-24-000102.md) | [58.6](/filings/0001516513-25-000012.md) | [41.9 d](/filings/0001516513-26-000025.md) | [46.1](/filings/0001516513-25-000093.md) | [53.1](/filings/0001516513-25-000111.md) | [79.9](/filings/0001516513-26-000006.md) | [48.7 d](/filings/0001516513-26-000025.md) | [54.5](/filings/0001516513-26-000040.md) | [63.7](/filings/0001516513-25-000111.md) | [71.9](/filings/0001516513-26-000006.md) | [24.8 d](/filings/0001516513-26-000025.md) | [33.6](/filings/0001516513-26-000040.md) |
| Income tax | $m | [9.1](/filings/0001516513-24-000102.md) | [15.1](/filings/0001516513-25-000012.md) | [7.3 d](/filings/0001516513-26-000025.md) | [11.8](/filings/0001516513-25-000093.md) | [18.0](/filings/0001516513-25-000111.md) | [14.6](/filings/0001516513-26-000006.md) | [(4.1) d](/filings/0001516513-26-000025.md) | [10.8](/filings/0001516513-26-000040.md) | [10.9](/filings/0001516513-25-000111.md) | [19.2](/filings/0001516513-26-000006.md) | [13.0 d](/filings/0001516513-26-000025.md) | [16.0](/filings/0001516513-26-000040.md) |
| Net income | $m | [30.6](/filings/0001516513-24-000102.md) | [48.0](/filings/0001516513-25-000012.md) | [40.6 d](/filings/0001516513-26-000025.md) | [41.4](/filings/0001516513-25-000093.md) | [44.2](/filings/0001516513-25-000111.md) | [75.2](/filings/0001516513-26-000006.md) | [62.5 d](/filings/0001516513-26-000025.md) | [53.3](/filings/0001516513-26-000040.md) | [62.1](/filings/0001516513-25-000111.md) | [61.6](/filings/0001516513-26-000006.md) | [19.1 d](/filings/0001516513-26-000025.md) | [24.3](/filings/0001516513-26-000040.md) |
| Diluted EPS | $ per share | [0.15](/filings/0001516513-24-000102.md) | [0.24](/filings/0001516513-25-000012.md) | not reported | [0.21](/filings/0001516513-25-000093.md) | [0.22](/filings/0001516513-25-000111.md) | [0.37](/filings/0001516513-26-000006.md) | not reported | [0.27](/filings/0001516513-26-000040.md) | [0.31](/filings/0001516513-25-000111.md) | [0.31](/filings/0001516513-26-000006.md) | not reported | [0.13](/filings/0001516513-26-000040.md) |
| Basic EPS | $ per share | [0.16](/filings/0001516513-24-000102.md) | [0.26](/filings/0001516513-25-000012.md) | not reported | [0.22](/filings/0001516513-25-000093.md) | [0.24](/filings/0001516513-25-000111.md) | [0.40](/filings/0001516513-26-000006.md) | not reported | [0.28](/filings/0001516513-26-000040.md) | [0.33](/filings/0001516513-25-000111.md) | [0.33](/filings/0001516513-26-000006.md) | not reported | [0.13](/filings/0001516513-26-000040.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | FY2024 (2024-03-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [108](/filings/0001516513-23-000084.md) | [123](/filings/0001516513-24-000009.md) | [96.8](/filings/0001516513-25-000056.md) | [111](/filings/0001516513-24-000064.md) | [184](/filings/0001516513-24-000102.md) | [165](/filings/0001516513-25-000012.md) | [210](/filings/0001516513-26-000025.md) | [137](/filings/0001516513-25-000093.md) | [169](/filings/0001516513-25-000111.md) | [64.8](/filings/0001516513-26-000006.md) | [219](/filings/0001516513-26-000040.md) | [274](/filings/0001516513-26-000040.md) |
| Current assets | $m | [863](/filings/0001516513-23-000084.md) | [841](/filings/0001516513-24-000009.md) | [913](/filings/0001516513-25-000056.md) | [908](/filings/0001516513-24-000064.md) | [958](/filings/0001516513-24-000102.md) | [1,013](/filings/0001516513-25-000012.md) | [1,089](/filings/0001516513-26-000025.md) | [1,034](/filings/0001516513-25-000093.md) | [1,092](/filings/0001516513-25-000111.md) | [993](/filings/0001516513-26-000006.md) | [944](/filings/0001516513-26-000040.md) | [914](/filings/0001516513-26-000040.md) |
| Total assets | $m | [1,026](/filings/0001516513-23-000084.md) | [1,001](/filings/0001516513-24-000009.md) | [1,079](/filings/0001516513-25-000056.md) | [1,073](/filings/0001516513-24-000064.md) | [1,119](/filings/0001516513-24-000102.md) | [1,172](/filings/0001516513-25-000012.md) | [1,264](/filings/0001516513-26-000025.md) | [1,204](/filings/0001516513-25-000093.md) | [1,257](/filings/0001516513-25-000111.md) | [1,157](/filings/0001516513-26-000006.md) | [1,124](/filings/0001516513-26-000040.md) | [1,084](/filings/0001516513-26-000040.md) |
| Current liabilities | $m | [123](/filings/0001516513-23-000084.md) | [105](/filings/0001516513-24-000009.md) | [147](/filings/0001516513-25-000056.md) | [135](/filings/0001516513-24-000064.md) | [132](/filings/0001516513-24-000102.md) | [116](/filings/0001516513-25-000012.md) | [156](/filings/0001516513-26-000025.md) | [160](/filings/0001516513-25-000093.md) | [140](/filings/0001516513-25-000111.md) | [150](/filings/0001516513-26-000006.md) | [155](/filings/0001516513-26-000040.md) | [150](/filings/0001516513-26-000040.md) |
| Total liabilities | $m | [154](/filings/0001516513-23-000084.md) | [136](/filings/0001516513-24-000009.md) | [178](/filings/0001516513-25-000056.md) | [160](/filings/0001516513-24-000064.md) | [157](/filings/0001516513-24-000102.md) | [141](/filings/0001516513-25-000012.md) | [182](/filings/0001516513-26-000025.md) | [179](/filings/0001516513-25-000093.md) | [162](/filings/0001516513-25-000111.md) | [178](/filings/0001516513-26-000006.md) | [173](/filings/0001516513-26-000040.md) | [168](/filings/0001516513-26-000040.md) |
| Shareholders' equity | $m | [871](/filings/0001516513-25-000012.md) | [865](/filings/0001516513-25-000012.md) | [901](/filings/0001516513-26-000025.md) | [914](/filings/0001516513-25-000111.md) | [961](/filings/0001516513-26-000006.md) | [1,031](/filings/0001516513-26-000006.md) | [1,083](/filings/0001516513-26-000040.md) | [1,026](/filings/0001516513-26-000040.md) | [1,096](/filings/0001516513-26-000006.md) | [979](/filings/0001516513-26-000006.md) | [951](/filings/0001516513-26-000040.md) | [916](/filings/0001516513-26-000040.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | Q4 FY2024 (2024-03-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q4 FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q4 FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [12.9 d](/filings/0001516513-24-000102.md) | [50.1 d](/filings/0001516513-25-000012.md) | [63.9 d](/filings/0001516513-26-000025.md) | [41.2](/filings/0001516513-25-000093.md) | [68.3 d](/filings/0001516513-25-000111.md) | [65.2 d](/filings/0001516513-26-000006.md) | [98.5 d](/filings/0001516513-26-000025.md) | [62.1](/filings/0001516513-26-000040.md) | [93.9 d](/filings/0001516513-25-000111.md) | [60.9 d](/filings/0001516513-26-000006.md) | [110 d](/filings/0001516513-26-000025.md) | [42.0](/filings/0001516513-26-000040.md) |
| Capital expenditure | $m | [0.0 d](/filings/0001516513-24-000102.md) | [0.0 d](/filings/0001516513-25-000012.md) | [0.0 d](/filings/0001516513-26-000025.md) | [0.0](/filings/0001516513-24-000064.md) | [0.0 d](/filings/0001516513-24-000102.md) | [0.0 d](/filings/0001516513-25-000012.md) | [0.0 d](/filings/0001516513-26-000025.md) | [0.0](/filings/0001516513-26-000040.md) | not reported | not reported | not reported | [0.1](/filings/0001516513-26-000040.md) |
| Share repurchases | $m | [164 d](/filings/0001516513-24-000102.md) | [76.8 d](/filings/0001516513-25-000012.md) | [17.7 d](/filings/0001516513-26-000025.md) | [51.2](/filings/0001516513-25-000093.md) | [23.0 d](/filings/0001516513-25-000111.md) | [19.3 d](/filings/0001516513-26-000006.md) | [26.8 d](/filings/0001516513-26-000025.md) | [122](/filings/0001516513-26-000040.md) | [21.9 d](/filings/0001516513-25-000111.md) | [197 d](/filings/0001516513-26-000006.md) | [90.5 d](/filings/0001516513-26-000025.md) | [91.6](/filings/0001516513-26-000040.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q2 FY2023 (2022-09-30) | Q3 FY2023 (2022-12-31) | Q1 FY2024 (2023-06-30) | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [214](/filings/0001516513-23-000084.md) | [212](/filings/0001516513-24-000009.md) | [212](/filings/0001516513-24-000064.md) | [209](/filings/0001516513-24-000102.md) | [200](/filings/0001516513-25-000012.md) | [199](/filings/0001516513-25-000093.md) | [200](/filings/0001516513-25-000111.md) | [202](/filings/0001516513-26-000006.md) | [201](/filings/0001516513-26-000040.md) | [201](/filings/0001516513-25-000111.md) | [199](/filings/0001516513-26-000006.md) | [191](/filings/0001516513-26-000040.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:41 ET. No prices; not investment advice.